Alpha 2.0
Login Register
» Articles » PMID: 38315102

The Future of International Classification of Diseases Coding in Steatotic Liver Disease: An Expert Panel Delphi Consensus Statement

Overview
Journal Hepatol Commun
Specialty Gastroenterology
Date 2024 Feb 5
PMID 38315102
Authors
Hannes Hagstrom
Leon A Adams
Alina M Allen
Christopher D Byrne
Yoosoo Chang
Ajay Duseja
Henning Gronbaek
Mona H Ismail
Peter Jepsen
Fasiha Kanwal
Jennifer Kramer
Rohit Loomba
Henry E Mark
Philip N Newsome
Mary E Rinella
Ian A Rowe
Seungho Ryu
Arun Sanyal
Jorn M Schattenberg
Marina Serper
Nick Sheron
Tracey G Simon
C Wendy Spearman
Elliot B Tapper
Marcela Villota-Rivas
Sarah H Wild
Vincent Wai-Sun Wong
Yusuf Yilmaz
Shira Zelber-Sagi
Fredrik Aberg
Jeffrey V Lazarus
Affiliations
Soon will be listed here.
Abstract

Background: Following the adoption of new nomenclature for steatotic liver disease, we aimed to build consensus on the use of International Classification of Diseases codes and recommendations for future research and advocacy.

Methods: Through a two-stage Delphi process, a core group (n = 20) reviewed draft statements and recommendations (n = 6), indicating levels of agreement. Following revisions, this process was repeated with a large expert panel (n = 243) from 73 countries.

Results: Consensus ranged from 88.8% to 96.9% (mean = 92.3%).

Conclusions: This global consensus statement provides guidance on harmonizing the International Classification of Diseases coding for steatotic liver disease and future directions to advance the field.

Citing Articles

Endothelial Dysfunction and Liver Cirrhosis: Unraveling of a Complex Relationship.

Nesci A, Ruggieri V, Manilla V, Spinelli I, Santoro L, Di Giorgio A Int J Mol Sci. 2024; 25(23).

PMID: 39684569 PMC: 11640898. DOI: 10.3390/ijms252312859.

Identifying metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus using clinic-based prediction tools.

Alkaabi J, Afandi B, Alhaj O, Kanwal D, Agha A Front Med (Lausanne). 2024; 11:1425145.

PMID: 39386740 PMC: 11461212. DOI: 10.3389/fmed.2024.1425145.

Steatotic Liver Disease in Pediatric Obesity and Increased Risk for Youth-Onset Type 2 Diabetes.

Putri R, Casswall T, Danielsson P, Marcus C, Hagman E Diabetes Care. 2024; 47(12):2196-2204.

PMID: 39373987 PMC: 11655408. DOI: 10.2337/dc24-1236.

Timely Follow-Up After a First Diagnosis of Cirrhosis is Associated With Reduced Mortality but No Impact on Rehospitalisations: A Population-Based Cohort of 8852 Patients.

Schechter M, Widman L, Wester A, Shang Y, Stal P, Fortune B Aliment Pharmacol Ther. 2024; 61(1):109-121.

PMID: 39354777 PMC: 11636062. DOI: 10.1111/apt.18309.

Changes in the epidemiological trends of primary liver cancer in the Asia-Pacific region.

Danpanichkul P, Suparan K, Sukphutanan B, Kaeosri C, Tothanarungroj P, Sirimangklanurak S Sci Rep. 2024; 14(1):19544.

PMID: 39174722 PMC: 11341810. DOI: 10.1038/s41598-024-70526-z.

References
1.
Rinella M, Lazarus J, Ratziu V, Francque S, Sanyal A, Kanwal F . A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023; 79(6):1542-1556. DOI: 10.1016/j.jhep.2023.06.003. View
2.
Hagstrom H, Vessby J, Ekstedt M, Shang Y . 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol. 2023; 80(2):e76-e77. DOI: 10.1016/j.jhep.2023.08.026. View
3.
Lazarus J, Mark H, Allen A, Arab J, Carrieri P, Noureddin M . A global research priority agenda to advance public health responses to fatty liver disease. J Hepatol. 2023; 79(3):618-634. DOI: 10.1016/j.jhep.2023.04.035. View
4.
Ratziu V, Boursier J . Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD. J Hepatol. 2023; 80(2):e51-e52. DOI: 10.1016/j.jhep.2023.07.017. View
5.
Hagstrom H, Adams L, Allen A, Byrne C, Chang Y, Gronbaek H . Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement. Hepatology. 2021; 74(1):474-482. PMC: 8515502. DOI: 10.1002/hep.31726. View